Eaton Vance Management’s Nektar Therapeutics NKTR Stock Holding History

Eaton Vance Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-83	Closed	-$17K	–	2392
2021 Q4	$17K	Sell	83 -29	-26%	-$6.29K	﹤0.01%	2428
2021 Q3	$4K	Sell	112 -12	-10%	-$2.88K	﹤0.01%	1844
2021 Q2	$32K	Buy	124 +11	+10%	+$3.04K	﹤0.01%	2301
2021 Q1	$34K	Buy	+113	New	+$35.2K	﹤0.01%	1895
2018 Q3	–	Sell	-1,064	Closed	-$779K	–	1207
2018 Q2	$779K	Buy	+1,064	New	+$1.23M	﹤0.01%	934

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Eaton Vance Management's NKTR Position: Q1 2022 in Review

Eaton Vance Management sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 83 shares — an estimated $17K sold.

Eaton Vance Management first reported a position in NKTR in Q2 2018 and held it in 5 quarters. The position peaked at $779K in Q2 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

Eaton Vance Management reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 83 Nektar Therapeutics shares in Q1 2022, an estimated $17K.
Eaton Vance Management first reported a position in Nektar Therapeutics in Q2 2018 and held it in 5 quarters.
Eaton Vance Management's Nektar Therapeutics position peaked at $779K in Q2 2018.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.